February 12, 2018
Authored and Edited by Glen Cheng, M.D.; Shana K. Cyr, Ph.D.
On February 5, 2018, FDA released a reminder that NDA and ANDA holders’ one-time reports on marketing status under the FDA Reauthorization Act of 2017 (FDARA) are due on February 14, 2018.
The reports must indicate whether each drug in the active section of the Orange Book (1) is available for sale, (2) has been withdrawn from sale, or (3) was never available for sale.
If all of an NDA or ANDA holder’s listed drugs are available for sale, the report should expressly state that the holder has reviewed the information published in the Orange Book and that all listed drugs are available for sale.
If one or more of an NDA or ANDA holder’s drugs has been withdrawn from sale, the report should identify each withdrawn drug’s National Drug Code; established name; proprietary name, if applicable; NDA or ANDA number; and strength; as well as the date on which it is expected to no longer be available or was no longer available for sale; and the reason(s) for the withdrawal.
If one or more of an NDA or ANDA holder’s drugs was never available for sale, the report should include each such drug’s established name; proprietary name, if applicable; NDA or ANDA number; and strength; as well as the date on which the drug will be available for sale, if known and applicable; and the reason(s) for not marketing the drug after approval.
The reporting requirements can be satisfied by submitting a letter to each applicable NDA or ANDA file through the electronic submissions gateway as part of a single grouped submission. FDA recommends that the submissions be identified as “MARKETING STATUS REPORT / ONE-TIME UPDATE.”
Readers are encouraged to read the reminder, also available on the FDA website, as well as the governing FDARA provisions.
Copyright © 2018 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
INCONTESTABLE® Blog
April 19, 2024
At the PTAB Blog
IPR and PGR Statistics for Final Written Decisions Issued in February 2024
April 16, 2024
INCONTESTABLE® Blog
April 4, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.